glp 1 triple agonist LY3437943, a novel glucagon, GIP, and GLP-1 receptor for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism Trends in the Development of
Description
contributed to study design, data collection, raw data verification, data analysis, data interpretation, and drafting and revisions of the manuscript
Shingu K, Helfritz A, Zielinska-Skowronek M, et al
11 (2003): 68256830, 10.1073/pnas.0631828100
DAlessio D
Given that the benefits of semaglutide stem from weight lossmediated metabolic improvements, stopping it may lead to recurrence of hepatic steatosis and fibrosis
Sellam, J
